Compare Cronos Group Inc (CRON) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Nomura Holdings Inc — how do they compare? Cronos Group Inc trades at $3.11 (market cap $1.14B), while Nomura Holdings Inc trades at $9.94 (market cap $28.46B). The key difference: Nomura Holdings Inc is far larger — about 25× Cronos Group Inc's market cap, and Nomura Holdings Inc pays a 3.31% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | NMR | |
|---|---|---|
Market Cap | $1.14B | $28.46B |
Sector | Health | Financials |
52-Week High | $3.27 | $10.04 |
52-Week Low | $2.30 | $6.73 |
Enterprise Value | $341.13M | — |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Nomura Holdings (NMR) trades at $9.82, down 1.31% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong revenue growth, with 2025 revenue reaching $1.66 trillion and net income of $340.74 billion, yielding a robust net margin of 20.4%. Recent earnings show a mix of beats and misses, with Q2 2026 EPS beating expectations. Analyst sentiment is mixed, with a 'Hold' consensus but positive momentum coverage in financial media.
The outlook for NMR is supported by fundamental strength in profitability and revenue expansion, though cash flow volatility and rising debt-to-asset ratios pose risks. The stock presents a value opportunity with a P/E of 11.59, but investors should weigh consistent earnings performance against macroeconomic and sector-specific headwinds affecting financial stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
